Impact of N-acetylcysteine Infusion and Intralipid Infusion on Myocardial Injury in Aluminum Phosphide Toxicity
Primary Purpose
Myocardial Injury
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
N-acetyl cysteine
Sponsored by

About this trial
This is an interventional treatment trial for Myocardial Injury focused on measuring Aluminum phosphide poisonings, Intralipid emulsion, N-acetylcystiene, Myocardial injury, Echocardiography
Eligibility Criteria
Inclusion Criteria:
- Presentation with symptomatic acute ALP poisoning.
- History of exposure including reliable identification of the compound based on the container brought by patient's relatives.
- The suggestive clinical manifestations following shortly after a single exposure to ALP.
Exclusion Criteria:
- Co-ingestion or exposure to other substances in addition to ALP.
- Patients had major medical conditions (e.g., cardiovascular disease, renal or hepatic failure).
- Patients received treatment in any hospital or medical center before admission - other than emergency department of Assiut University Hospital.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
N-acetyl cysteine (NAC)
Intra lipid emulsion (ILE)
Arm Description
Conservative management + ILE infusion 10 ml/hr + N-acetyl cysteine (NAC) infusion 150 mg/kg body weight in 200 ml of 5% dextrose over 1 h, followed by 50 mg/kg body weight in 500 ml of 5% dextrose over 4 h, and then 100 mg/kg body weight in 1000 ml of 5% dextrose over 16 h.
Conservative management + ILE infusion 10 ml/hr + normal saline infusion
Outcomes
Primary Outcome Measures
Echocardiography
Follow up cardiac function by echocardiography focusing on LV EF
Secondary Outcome Measures
Renal function test
Effect on renal function by measuring serum creatinine and serum BUN
Total days of ICU stay
ICU stay
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05370729
Brief Title
Impact of N-acetylcysteine Infusion and Intralipid Infusion on Myocardial Injury in Aluminum Phosphide Toxicity
Official Title
Impact of Combining N-acetylcysteine Intravenous Infusion and Intralipid Emulsion Infusion Versus Intralipid Infusion Alone on Myocardial Injury in Aluminum Phosphide Toxicity
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
May 2022 (Anticipated)
Primary Completion Date
May 2024 (Anticipated)
Study Completion Date
May 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Assiut University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Assess impact of ILE and NAC in morbidity and mortality when used as adjuvant therapy to routine management of acute ALP poisoning.
Detailed Description
Aluminum phosphide (ALP) is one of the solid fumigant pesticides. In Egypt, ALP is extensively used to protect grains against insects and rodents. It is available in the form of tablets known as "grain tablet". Suicidal ingestion of ALP tablets is obviously increasing in developing countries. This is attributed to its wide use, free availability in the market, and its low cost.
Aluminum phosphide toxicity is extremely fatal. The conveyed mortality rate differs from 37-100%. More than 90% of patients die within the first 24 hours, mainly due to cardiac dysrhythmia. Despite continuous research, no effective antidote has been reported for this lethal poisoning so far. PH3 is phosphorus trihydride and solubility of phosphorus can affect PH3. Solubilities of phosphorus are as follows: In water: 1 part/300,000 parts water; in absolute alcohol: 1 g/400 mL. One gram phosphorus dissolves in 80 ml olive oil, 60 ml oil of turpentine, and about 100 mL of almond oil. So, PH3 might also have lipid soluble property and used IV lipid emulsion may counter its effects.
Intravenous lipid emulsion (ILE) is a sterile fat emulsion prepared for intravenous administration as a source of calories and essential fatty acids. Its main components include up to 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection. In addition, sodium hydroxide has been added to adjust the pH, so that the final pH is 8.
Based on animal models and clinical studies, ILE is an established antidote for local-anesthetic drugs systemic toxicity. Besides, ILE has been well used for resuscitation of severe toxicities caused by various lipophilic non-local anesthetic drugs.
N-acetylcysteine (NAC) is a well-studied compound which is commonly used in the treatment of paracetamol poisoning. It has shown to replenish cellular glutathione stores in addition to the strong antioxidant properties. NAC has shown to reduce mortality, hospitalization time, and need for mechanical ventilation in ALP poisoning. A cohort study by Agarwal reported survival benefit in patients who received treatment with NAC compared to the control group.
Brain natriuretic peptide (BNP) is an excellent biomarker because it can be detected in the early stages of ischemia and decreases shortly after ischemia allowing better detection of re-injury. A metabolite of BNP, Nterminal pro-BNP, NT-proBNP, is relatively easy to measure and predicts short and long term outcomes. BNP is a 32-amino-acid peptide synthesized predominantly from the ventricular myocardium and is released in proportion to the degree of wall stress. Although it has gained recent prominence in the diagnosis and treatment of heart failure, BNP has recently shown promise in predicting the extent of myocardial ischemia in acute coronary syndromes. For instance, the magnitude of BNP released between 1 and 7 days after a myocardial infarction is predictive of left ventricular dysfunction, heart failure, and mortality.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myocardial Injury
Keywords
Aluminum phosphide poisonings, Intralipid emulsion, N-acetylcystiene, Myocardial injury, Echocardiography
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
58 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
N-acetyl cysteine (NAC)
Arm Type
Experimental
Arm Description
Conservative management + ILE infusion 10 ml/hr + N-acetyl cysteine (NAC) infusion 150 mg/kg body weight in 200 ml of 5% dextrose over 1 h, followed by 50 mg/kg body weight in 500 ml of 5% dextrose over 4 h, and then 100 mg/kg body weight in 1000 ml of 5% dextrose over 16 h.
Arm Title
Intra lipid emulsion (ILE)
Arm Type
No Intervention
Arm Description
Conservative management + ILE infusion 10 ml/hr + normal saline infusion
Intervention Type
Drug
Intervention Name(s)
N-acetyl cysteine
Other Intervention Name(s)
NAC
Intervention Description
Intravenous infusion of NAC 150 mg/kg body weight in 200 ml of 5% dextrose over 1 h, followed by 50 mg/kg body weight in 500 ml of 5% dextrose over 4 h, and then 100 mg/kg body weight in 1000 ml of 5% dextrose over 16 h.
Primary Outcome Measure Information:
Title
Echocardiography
Description
Follow up cardiac function by echocardiography focusing on LV EF
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Renal function test
Description
Effect on renal function by measuring serum creatinine and serum BUN
Time Frame
24 hours
Title
Total days of ICU stay
Description
ICU stay
Time Frame
Up to two weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Presentation with symptomatic acute ALP poisoning.
History of exposure including reliable identification of the compound based on the container brought by patient's relatives.
The suggestive clinical manifestations following shortly after a single exposure to ALP.
Exclusion Criteria:
Co-ingestion or exposure to other substances in addition to ALP.
Patients had major medical conditions (e.g., cardiovascular disease, renal or hepatic failure).
Patients received treatment in any hospital or medical center before admission - other than emergency department of Assiut University Hospital.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tassbeeh Kamal
Phone
01065656202
Email
tk.zanaty_92@med.aun.edu.eg
First Name & Middle Initial & Last Name or Official Title & Degree
Shimaa A Hassan, PHD, MD
Phone
01002953253
Email
shimaa.abbas@med.aun.edu.eg
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ola M Wahba, PHD, MD
Organizational Affiliation
Assiut University
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
26816450
Citation
Baruah U, Sahni A, Sachdeva HC. Successful management of aluminium phosphide poisoning using intravenous lipid emulsion: Report of two cases. Indian J Crit Care Med. 2015 Dec;19(12):735-8. doi: 10.4103/0972-5229.171412.
Results Reference
background
PubMed Identifier
23148565
Citation
Tehrani H, Halvaie Z, Shadnia S, Soltaninejad K, Abdollahi M. Protective effects of N-acetylcysteine on aluminum phosphide-induced oxidative stress in acute human poisoning. Clin Toxicol (Phila). 2013 Jan;51(1):23-8. doi: 10.3109/15563650.2012.743029. Epub 2012 Nov 14.
Results Reference
background
PubMed Identifier
25316977
Citation
Agarwal A, Robo R, Jain N, Gutch M, Consil S, Kumar S. Oxidative stress determined through the levels of antioxidant enzymes and the effect of N-acetylcysteine in aluminum phosphide poisoning. Indian J Crit Care Med. 2014 Oct;18(10):666-71. doi: 10.4103/0972-5229.142176.
Results Reference
background
PubMed Identifier
9244219
Citation
Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, Sugimoto Y, Kinoshita M. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997 Jul 15;96(2):509-16. doi: 10.1161/01.cir.96.2.509.
Results Reference
background
Learn more about this trial
Impact of N-acetylcysteine Infusion and Intralipid Infusion on Myocardial Injury in Aluminum Phosphide Toxicity
We'll reach out to this number within 24 hrs